{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:26:06Z","timestamp":1758875166974,"version":"3.41.2"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Primary central nervous system lymphoma (PCNSL) is a rare and aggressive variant of non-Hodgkin lymphoma. While PCNSL is often sensitive to induction high-dose methotrexate (HDMTX) based chemotherapy, recurrence rates remain high, approaching 50% within 5 years. The most common molecular alterations in PCNSL include mutations in MYD88 and CD79 and CDKN2A homozygous deletion. There are no predictive or prognostic molecular markers in PCNSL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective review of 40 patients with PCNSL treated at Thomas Jefferson University and Ohio State University between 2011 and 2023. We created a clinically annotated database of patient characteristics and outcomes. For 13 patients whose paraffin-embedded tissue was available for analysis, Illumina\u2019s Infinium Global Diversity Array with Cytogenetics was used to make copy number change calls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most commonly used induction chemotherapy regimens were HDMTX monotherapy and HDMTX with rituximab. The overall response rate to induction chemotherapy was 75%. A total of 25% had resistant disease to induction chemotherapy. The median follow-up was 20.3 months. The median progression-free survival for the entire cohort was 30.64 months (range 3.42\u201357.86 months); 2.56 months for the resistant group and 44.88 months for the sensitive group (P-value\u2005&amp;lt;\u2005.001). The median overall survival for the entire cohort was 64.8 months (range 41.47\u201388.13 months); 13.97 months for the resistant group and 81.43 months for the sensitive group (P-value\u2005=\u2005.046).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The initial response to induction chemotherapy is an important prognostic factor in PCNSL. There is a need for improved predictive biomarkers of response to treatment in PNCLS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf082","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T10:45:05Z","timestamp":1745491505000},"source":"Crossref","is-referenced-by-count":1,"title":["Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-8519","authenticated-orcid":false,"given":"Louis","family":"Cappelli","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Thomas Jefferson University , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Kayne","sequence":"additional","affiliation":[{"name":"Department of Internal Medi , Philadelphia, Pennsylvania ,","place":["USA"]},{"name":"cine, Thomas Jefferson University , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Neurolog , New York, New York ,","place":["USA"]},{"name":"y, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Elguindy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center , Columbus, Ohio ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Department of Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, Utah ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The James Cancer Hospital at The Ohio State University Wexner Medical Center , Columbus, Ohio ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ubaldo Martinez","family":"Outschoorn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thomas Jefferson University , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thomas Jefferson University , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3912","authenticated-orcid":false,"given":"Wenyin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Thomas Jefferson University , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iyad","family":"Alnahhas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Thomas Jefferson University , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"9","key":"2025062608280654900_CIT0001","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood."},{"issue":"28","key":"2025062608280654900_CIT0002","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","article-title":"Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma","volume":"24","author":"Gavrilovic","year":"2006","journal-title":"J Clin Oncol."},{"issue":"4","key":"2025062608280654900_CIT0003","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","article-title":"Combined modality therapy for primary CNS lymphoma","volume":"10","author":"DeAngelis","year":"1992","journal-title":"J Clin Oncol."},{"issue":"9700","key":"2025062608280654900_CIT0004","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet."},{"issue":"9","key":"2025062608280654900_CIT0005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood."},{"issue":"25","key":"2025062608280654900_CIT0006","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol."},{"issue":"5","key":"2025062608280654900_CIT0007","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025062608280654900_CIT0008","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/j.clml.2018.11.018","article-title":"Autologous stem-cell transplantation for primary central nervous system lymphoma: Systematic review and meta-analysis","volume":"19","author":"Alnahhas","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2025062608280654900_CIT0009","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00277-002-0498-8","article-title":"Primary central nervous system (CNS) lymphoma in immunocompetent patients","volume":"81","author":"Plasswilm","year":"2002","journal-title":"Ann Hematol."},{"issue":"11","key":"2025062608280654900_CIT0010","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/neuonc\/noae115","article-title":"Outcomes and relapse patterns in primary central nervous system","volume":"26","author":"Tringale","year":"2024","journal-title":"Neuro Oncol"},{"issue":"3","key":"2025062608280654900_CIT0011","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","article-title":"MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas","volume":"3","author":"Nayyar","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"2025062608280654900_CIT0012","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat Commun."},{"issue":"7","key":"2025062608280654900_CIT0013","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood."},{"issue":"22","key":"2025062608280654900_CIT0014","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol."},{"key":"2025062608280654900_CIT0015","doi-asserted-by":"crossref","first-page":"878618","DOI":"10.3389\/fgene.2022.878618","article-title":"Whole-genome\/exome sequencing uncovers mutations and copy number variations in primary diffuse large B-cell lymphoma of the central nervous system","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Genet."},{"issue":"6","key":"2025062608280654900_CIT0016","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: An intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025062608280654900_CIT0017","first-page":"vdad097","article-title":"Long-term outcomes with reduced-dose whole-brain radiotherapy and a stereotactic radiosurgery boost for primary central nervous system lymphoma","volume":"5","author":"Foreman","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"2","key":"2025062608280654900_CIT0018","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11060-020-03444-5","article-title":"Outcomes after stereotactic radiosurgery for CNS lymphoma","volume":"147","author":"Palmer","year":"2020","journal-title":"J Neurooncol."},{"issue":"3","key":"2025062608280654900_CIT0019","first-page":"422","article-title":"Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: Imaging analysis of the ANOCEF-GOELAMS prospective randomized trial","volume":"19","author":"Tabouret","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025062608280654900_CIT0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12987-017-0064-3","article-title":"Patterns of relapse in primary central nervous system lymphoma: Inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease","volume":"14","author":"Ambady","year":"2017","journal-title":"Fluids Barriers CNS"},{"issue":"29","key":"2025062608280654900_CIT0021","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2006.06.7165","article-title":"Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes","volume":"24","author":"Jahnke","year":"2006","journal-title":"J Clin Oncol."},{"issue":"12","key":"2025062608280654900_CIT0022","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/neuonc\/noae146","article-title":"Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG PET\/CT","volume":"26","author":"Oh","year":"2024","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf082\/62997207\/vdaf082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf082\/62997207\/vdaf082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf082\/62997207\/vdaf082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:28:14Z","timestamp":1750940894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf082\/8118981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf082","relation":{},"ISSN":["2632-2498"],"issn-type":[{"type":"electronic","value":"2632-2498"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf082"}}